Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, clinical-stage biotech company Repros Therapeutics (NASDAQ: RPRX ) has received the dreaded one-star ranking.
With that in mind, let's take a closer look at Repros and see what CAPS investors are saying about the stock right now.
Repros facts
Headquarters (founded) | The Woodlands, Texas (1987) |
Market Cap | $208.1 million |
Industry | Pharmaceuticals |
Trailing-12-Month EBITDA | ($12.7 million) |
Management | CEO Joseph Podolski (since 1992) |
Trailing-12-Month Return on Equity | (69.9%) |
Cash/Debt | $29.6 million / $0 |
Competitors | Abbott Labs |
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 54% of the 131 members who have rated Repros believe the stock will underperform the S&P 500 going forward.
Just last week, one of those Fools, All-Star TerryHogan, succinctly summed up the Repros bear case for our community:
They're burning through cash like a former child-star on a [V]egas bender, and they're handing out shares like they're breath mints at a halitosis convention. They have no revenues to speak of (in fact they don't have any revenue at all). And while the latest announcement about their clinical trial isn't exactly a nail in the coffin, it could be a sign of greater malfeasance.
If you want market-topping returns, you need to protect your portfolio from any undue risk. Luckily, we've found another stock we are incredibly excited about -- excited enough to dub it "The Motley Fool's Top Stock for 2013." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so click here to access it now.
Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.
No comments:
Post a Comment